2026-10-19T04:52:53Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/120202026-10-18T21:13:19Zopenairedrivercom_ebyu_10000col_ebyu_10001

The Effects of Vaccines on the Sequelae Rates of Recurrent Infections and the Severity of Pulmonary COVID-19 Infection by ImagingBahadir, SuzanKabacaoglu, EbruMemis, Kemal BugraHasan, Hasan IlksenAydin, Sonaycoronavirus diseaselung complicationsreinfectionsequelaethorax CTvaccinationC reactive proteincoronavacD dimerferritinfibrinogenhemoglobinprocalcitoninSARS-CoV-2 vaccinetozinameranadultagedArticleartificial ventilationatelectasisbronchiectasiscomputer assisted tomographycontrolled studycoronavirus disease 2019diagnostic test accuracy studydisease severitydry coughfemalefeverfibrosisAlthough vaccines have been shown to reduce the number of COVID-19 infection cases significantly, vaccine-related reactions, long COVID-19 syndrome, and COVID-19 infection following vaccination continue to be a burden on healthcare services and warrant further scientific research. The purpose of this study was to research the severity of pulmonary COVID-19 infection following vaccination and the sequelae rates of recurrent infections in vaccinated cases by imaging. Patients who underwent follow-up CTs at 1 month, 3 months, and 6 months in our hospital with a diagnosis of COVID-19 were scanned retrospectively. Furthermore, all essential information was gathered from patients’ immunization records. The major findings of our study were: (1) sequelae were frequently observed in unvaccinated cases; (2) the correlation between vaccination status and the severity of sequelae was significant; (3) there was not any significant relationship between the vaccine type and the severity of sequelae; and (4) hematocrit, hemoglobin, and lymphocyte parameters may be used as predictors of sequelae rates. COVID-19 infection, although reduced in prevalence following the development of vaccines, still remains a public health concern because of reinfection. Vaccination not only appears to protect against primary infection, but also seems to reduce reinfection and sequalae rates following reinfection. © 2023 by the authors.Multidisciplinary Digital Publishing Institute (MDPI)2023Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12020https://doi.org/10.3390/vaccines110813212076-393XenVaccinesinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12020